Navigation Links
ARIUS presents new findings for anti-cancer antibody programs at AACR
Date:4/15/2008

nstrated that treatment with ARIUS' CD9 targeting antibody, AR40A746.2.3, induced apoptosis in BxPC-3 pancreatic cancer cell as a monotherapy. Moreover, apoptosis is achieved through inhibition of the AKT pathway, commonly believed to be an important pathway for cancer cell survival.

New immunohistochemistry (IHC) studies using this antibody showed that CD9 is expressed in a variety of human tumor samples, resulting in moderate to high levels of staining in 61/82 (73.5%) of tumor cells from various organs including pancreas, prostate, stomach and liver. The antibody demonstrated potent anti-tumor efficacy in in vivo models of pancreatic, breast and AML cancers and treatment led to a decrease in phosphorylation of several receptor tyrosine kinases.

CD9 is highly and differentially expressed in AML versus normal CD34+CD38- stem cells. Experiments strongly suggest that ARIUS' CD9 targeting antibody inhibits human AML outgrowth in pre-clinical studies. In secondary transplantation experiments, treatment with ARIUS' CD9 targeting antibody dramatically reduced the self-renewal capacity of AML cancer stem cells. CD9 is the first description of a marker that is differentially expressed on cancer versus normal stem cells.

Trop-2 Signal Transduction Program

AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy. Abstract Number 3990. Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

ARIUS shows its Trop-2 targeting antibody, AR47A6.4.2, is involved in the MAPK pathway. This antibody demonstrated potent anti-tumor efficacy in human pancreatic, breast, colon and prostate cancer models. In combination with Gemcitabine, this antibody also inhibited tumor growth by 93% in a human pancreatic cancer model. ARIUS' Trop-2 targeting antibody is the only naked therapeutic antibody targeti
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ARIUS announces first quarter fiscal 2008 financial results
2. ARIUS 2008 Annual and Special Meeting of Shareholders
3. ARIUS recognized for entrepreneurial excellence
4. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
7. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
8. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
9. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
10. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
11. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... a unit of Fiserv, Inc. , and Union ... iLINK Remote Deposit product to the bank's commercial banking customers. ... for remote corporate capture and deposit services, allows commercial banking ... directly from their offices, eliminating trips to the branch and ...
... Software, Inc . has entered into agreements to provide its ... for whom it may become a key retention tool. ... parts of the bundle play a role in staff recruitment ... nursing shortages. , ,Shift bidding, for example, has become ...
... Wis. - The Wisconsin Angel Network , hoping ... new ePlan system to enable companies to use rich media ... ePlan, which uses Mediasite technology from Sonic Foundry , ... effort and expense. For about the cost of an airplane ...
Cached Biology Technology:Medical software may be a retention tool 2Angel network introduces ePlan 2
(Date:7/10/2014)... Foundation, a nonprofit organization funding cutting-edge, innovative research ... glaucoma and macular degeneration, today announced the recipients ... scientists in 19 U.S. states, the District of ... . , With these latest grants, BrightFocus ... research funding in 2014. , The research projects ...
(Date:7/10/2014)... ANN ARBOR Because the strong currents in the ... rupture of the oil pipeline beneath the channel would ... and Huron, according to a new University of Michigan ... one scenario examined in the study and accompanying animations, ... and Round Island after 12 hours and Bois Blanc ...
(Date:7/10/2014)... University Medical Center (CUMC) researchers have created a way ... pigmentosa (RP), a leading cause of vision loss. The ... induced pluripotent stem (iPS) cell technology to transform skin ... a patient-specific model for disease study and preclinical testing. ... Tsang, MD, PhD, showed that a form of RP ...
Breaking Biology News(10 mins):BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... nerve cell degeneration plays a crucial role. In the future, ... generation and/or migration mechanism. These findings have been published in ... . Until only a few years ago, neurogenesis the ... impossible in the adult brain. The textbooks asserted that dead ...
... Yehezkel Ben-Ari, winner of the 2009 Inserm Grand Prix. ... to paying tribute to outstanding,work performed in its laboratories ... diversity and wealth of activities involved in today,s biological, ... the men and women who carry out and,drive this ...
... world first, a Monash University-led international research team has ... the next generation of solar cells. Scientists at ... of Wollongong and Ulm in Germany, have produced tandem ... conversion efficiency compared with previously reported tandem dye-sensitised solar ...
Cached Biology News:New source discovered for the generation of nerve cells in the brain 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Innovation puts next-generation solar cells on the horizon 2
Protein Marker Detection Pack contains biotinylate...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: